PMID- 18401214
OWN - NLM
STAT- MEDLINE
DCOM- 20080604
LR  - 20191110
IS  - 1527-5299 (Print)
IS  - 1527-5299 (Linking)
VI  - 14
IP  - 2
DP  - 2008 Mar-Apr
TI  - Baseline characteristics of patients randomized in The Resynchronization Reverses 
      Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study.
PG  - 66-74
AB  - The Resynchronization Reverses Remodeling in Systolic Left Ventricular 
      Dysfunction (REVERSE) study is a randomized controlled trial currently assessing 
      the safety and efficacy of cardiac resynchronization therapy in patients with 
      asymptomatic left ventricular (LV) dysfunction with previous symptoms of mild 
      heart failure. This paper describes the baseline characteristics of randomized 
      patients; 610 patients with New York Heart Association (NYHA) class II (82.3%) 
      heart failure or asymptomatic (NYHA class I) LV dysfunction with previous 
      symptoms (17.7%) were randomized in 73 centers. The mean age was 62.5+/-11.0 
      years, the mean LV ejection fraction was 26.7%+/-7.0%, and the mean LV 
      end-diastolic diameter was 66.9+/-8.9 mm. A total of 97% of patients were taking 
      angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 
      95.1% were taking beta-blockers, which were at the target dose in 35.1% of 
      patients. Compared with previous randomized cardiac resynchronization therapy 
      trials, REVERSE patients are on better pharmacologic treatment, are younger, and 
      have a narrower QRS width despite similar LV dysfunction.
FAU - Linde, Cecilia
AU  - Linde C
AD  - Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. 
      cecilia.linde@ki.se
FAU - Gold, Michael
AU  - Gold M
FAU - Abraham, William T
AU  - Abraham WT
FAU - Daubert, Jean-Claude
AU  - Daubert JC
CN  - REVERSE Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Congest Heart Fail
JT  - Congestive heart failure (Greenwich, Conn.)
JID - 9714174
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Angiotensin II Type 1 Receptor Blockers/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Arrhythmias, Cardiac/*therapy
MH  - *Cardiac Pacing, Artificial
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stroke Volume
MH  - Systole
MH  - Ventricular Dysfunction, Left/drug therapy/*therapy
MH  - Ventricular Remodeling/*physiology
EDAT- 2008/04/11 09:00
MHDA- 2008/06/05 09:00
CRDT- 2008/04/11 09:00
PHST- 2008/04/11 09:00 [pubmed]
PHST- 2008/06/05 09:00 [medline]
PHST- 2008/04/11 09:00 [entrez]
AID - 10.1111/j.1751-7133.2008.07613.x [doi]
PST - ppublish
SO  - Congest Heart Fail. 2008 Mar-Apr;14(2):66-74. doi: 
      10.1111/j.1751-7133.2008.07613.x.